| Theme |
New Perspectives of Molecular Biomarker in Dialysis Therapy |
| Title |
Biomarkers of gastrointestinal disease |
| Author |
Yasushi Hamaya |
Department of Molecular Diagnosis, Hamamatsu University School of Medicine |
| Author |
Mitsushige Sugimoto |
Center for Clinical Research, Hamamatsu University School of Medicine |
| Author |
Shigeru Kanaoka |
Department of Molecular Diagnosis, Hamamatsu University School of Medicine |
| Author |
Takahisa Furuta |
Center for Clinical Research, Hamamatsu University School of Medicine |
| Author |
Mutsuhiro Ikuma |
First Department of Medicine, Hamamatsu University School of Medicine |
| [ Summary ] |
Helicobacter pylori infection is a major risk factor for development of gastric cancer and peptic ulcers. Therefore, it is important to correctly diagnose H. pylori infections. Non-invasive methods, such as the urea breath test or detection of stool antigens and serum anti-H. pylori antibodies are recommended to detect H. pylori infection in patients receiving ongoing hemodialysis treatment. Moreover, because patients treated with hemodialysis are at a higher risk of developing some types of cancer, such as gastric cancer, new screening methods have been developed. These detect polymorphisms of inflammatory cytokine genes (i.e., IL-B-511 and TNF-A-857/-863/-1031) and renin-angiotensin system genes (i.e., CMA/B and AGT-20). Methods to detect fecal COX-2 and MMP-7 mRNA (fecal RNA testing) for colorectal cancer, are being developed. |